/
Other
Graves Disease
15
Pipeline Programs↗
22
Active Trials↗
8
Companies Involved↗
Graves disease is an emerging landscape with 15 programs across 8 companies. The most active players are Sanofi, Merida Biosciences, Biohaven Therapeutics Ltd.. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 16
Phase 25
Phase 33
Approved
No programs
Analysis
Modality Breakdown
63%
Small molecule
5 of 8 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 67% of 15 pipeline programs.
Analysis
Trial Status
38
clinical trials
Recruiting21 · 55%
Completed13 · 34%
Unknown status2 · 5%
Terminated1 · 3%
Enrolling by invitation1 · 3%
Clinical Trials
Trial Activity
38 trials
Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter
Recruiting·—·Phase 3·NCT04856488·182 enrolled
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05461820·240 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)